
Prior to SCM, Dr. Carol spent 20 years in the field of radiation oncology, where he was instrumental in several of the seminal developments in the field, including intensity modulated radiation therapy, image-guided radiation therapy, and inverse treatment planning. He was trained as a neurosurgeon at the University of Maryland, later combining his training and technology bent in the early days of stereotactic radiation therapy and stereotaxis to develop innovations in frameless and image-guided stereotactic surgery.
Dr. Carol received his BA with high honors as an Independent Scholar at Amherst College and his MD with Distinction in Research from the University of Rochester.
“I have a profound belief that there is the potential for therapeutic ultrasound to play a role in almost every medical therapeutic intervention,” said Dr. Carol. “I look forward to assisting the Foundation’s activities aimed at easing the path to commercialization in the focused ultrasound space.”
Related Articles:
Profile: SonaCare CEO Mark Carol